Armin Ghobadi

Also affiliated with American Rock Mechanics Association, Saint Louis University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 20 papers. Top paper: “Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial”.

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

Nature Medicine(2023)10.1038/s41591-022-02128-z

N/A

5.6DataRank · unranked

197 citations

Brian A. Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L. Johnson, Anthony J. Olszanski +39 more

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

New England Journal of Medicine(2017)10.1056/nejmoa1707447

N/A

1.3DataRank · unranked

5812 citations

Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson +41 more

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Journal of Clinical Oncology(2020)10.1200/jco.19.02104

N/A

1.0DataRank · unranked

800 citations

Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi, Yi Lin +23 more

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors

Frontiers in Oncology(2022)10.3389/fonc.2022.818679

N/A

0.830DataRank · unranked

20 citations

Marcus O. Butler, Russell K. Pachynski, Ryan J. Sullivan, Partow Kebriaei, Sarah Boross-Harmer +20 more

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

Nature Medicine(2022)10.1038/s41591-022-01916-x

N/A

0.799DataRank · unranked

205 citations

Regis Perbost, Frederick L. Locke, Michael D. Jain, Sarah Turcan, Corinne Danan +17 more

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

The Lancet(2025)10.1016/s0140-6736(24)02462-0

N/A

0.730DataRank · unranked

129 citations

Veronika Bachanova, Krish Patel, Jae H Park, Ian Flinn, Peter A Riedell +12 more

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Journal of Clinical Oncology(2024)10.1200/jco.23.02786

N/A

0.650DataRank · unranked

75 citations

Jay Y. Spiegel, Loretta J. Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin +27 more

CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells

Leukemia(2022)10.1038/s41375-022-01559-4

N/A

0.604DataRank · unranked

55 citations

Julie Ritchey, Matthew Cooper, Jessica Niswonger, Luisalberto Gonzalez, Emily Street +12 more

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Blood(2025)10.1182/blood.2025028387

N/A

0.531DataRank · unranked

19 citations

Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel +28 more

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation

Blood(2025)10.1182/blood.2024026497

N/A

0.447DataRank · unranked

10 citations

Mark A. Schroeder, Michael P. Rettig, Reyka G. Jayasinghe, Feng Gao, Jeremy Eisele +14 more

Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma

Advances in Therapy(2024)10.1007/s12325-024-02917-7

N/A

0.434DataRank · unranked

17 citations

Armin Ghobadi, Richard Maziarz, Krish Patel, Hil Hsu, Zihao Liu +4 more

Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7552

N/A

0.396DataRank · unranked

13 citations

Frederick L. Locke, Zhen‐Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi +15 more

Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Cancers(2022)10.3390/cancers14122932

N/A

0.330DataRank · unranked

8 citations

Vanessa A. Sanders, Priyanka Pullarkat, Stephanie Teja, Amber Salter, Marcus P. Watkins +13 more

Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation

Blood Advances(2020)10.1182/bloodadvances.2020001499

N/A

0DataRank · unranked

62 citations

Dongyun Yang, Myriam Labopin, Boris V. Afanasyev, Emanuele Angelucci, Asad Bashey +21 more

Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.07.015

N/A

0DataRank · unranked

19 citations

Armin Ghobadi, John F. Dipersio, Brian T. Hill, M. Shadman, Tania Jain +1 more

A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1872068

N/A

0DataRank · unranked

8 citations

Michael P. Rettig, Theresa Fletcher, Julie Ritchey, Leah Gehrs, Kyle McFarland +15 more

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

Blood Advances(2023)10.1182/bloodadvances.2023011489

N/A

0DataRank · unranked

26 citations

Miriam T. Jacobs, Feng Gao, Loretta J. Nastoupil, Jay Y. Spiegel, Yi Lin +21 more

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy

American Journal of Hematology(2024)10.1002/ajh.27283

N/A

0DataRank · unranked

4 citations

Hailin Wang, Zhen‐Huan Hu, Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson +18 more

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?

Frontiers in Oncology(2020)10.3389/fonc.2020.608916

N/A

0DataRank · unranked

21 citations

Armin Ghobadi, John F. Dipersio, Scott Goldsmith

The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

Blood(2022)10.1182/blood.2022016194

N/A

0DataRank · unranked

88 citations

Michael Slade, Hagop M. Kantarjian, Julio Alvarenga, Ibrahim Aldoss, Kahee A. Mohammed +16 more